Brief: Everest Medicines Subscribes For 15.8 Million ADSS OF I-MAB For $30.9 Million
01/08/2025 16:09
Aug 1 (Reuters) - Everest Medicines Ltd 1952.HK: SUBSCRIBES FOR 15.8 MILLION ADSS OF I-MAB FOR $30.9 MILLION Further company coverage: 1952.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region